# US 2019/0169136 A1 · Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169136 A1
- Document ID: US20190169136A1
- Status: Published application
- Kind: A1
- Application number: 16/323,691
- Filed: 2017-08-07
- Published: 2019-06-06
- Earliest claimed: 2016-08-08
- Assignees: Commissariat A L'energie Atomique Et Aux Energies Alternatives; Universite Grenoble Alpes; Universite D'Aix-Marseille
- Applicants: Commissariat a l'Energie Atomique et aux Energies Alternatives; Universite Grenoble Alpes; Universite d'Aix Marseille
- Inventors: Marie-Odile Fauvarque; Magda Mortier; Catherine Pillet; Carmen Aguilar; Emmanuelle Soleilhac; Caroline Barette; Vincent Remusat; Thierry Terme; Patrice Vanelle
- Web page: https://patentgrep.com/patent/US20190169136A1

## CPC

- C07D 241/52: Oxygen atoms
- A61P 35/00: Antineoplastic agents
- C07D 221/06: Ring systems of three rings
- C07D 241/38: with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D 263/52: condensed with carbocyclic rings or ring systems
- C07D 263/60: Naphthoxazoles; Hydrogenated naphthoxazoles
- C07D 263/62: having two or more ring systems containing condensed 1,3-oxazole rings
- C07D 403/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.

## Claims

### Claim 1

A method for the treatment of cancer comprising administration to a subject in need thereof a compound of formula (I):
wherein:
A is selected from the group comprising:
Ra and Rb each independently represent:
when A is A1 or A3, a group of one of the following formulae:
when A is A2, H or a group of one of the following formulae:
provided that at least one of Ra and Rb is not H;
RY and RZ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the carbon atom to which they are attached a C3-C10 cycloalkyl group;
X represents Cl or a group the following formula:
RX represents a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an aryl group, in particular a phenyl or naphtyl group, a C5-C10-membered heteroaryl;
said C1-C10 linear or branched alkyl group, and C3-C10 cycloalkyl group being optionally substituted by at least one group selected from:
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
a —ORi group;
an amine of formula —NRi′Ri″;
said aryl and C5-C10-membered heteroaryl being optionally substituted by at least one group selected from:
a C1-C10 linear or branched alkyl group;
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
an halogen;
a —ORi group; two adjacent —ORi groups forming possibly with the two C atoms bearing said —ORi groups a 1,4-dioxane ring;
an amine of formula —NRi′Ri″;
a nitrile;
a nitro group;
a CF3 group;
Ri and Rii each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group;
Ri′ and Ri″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group;
Rii′ and Rii″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group.

### Claim 2 (depends on 1)

The method according to claim 1, wherein in formula (I):
A is selected from the group comprising:
Ra and Rb each independently represent:
when A is A1 or A3, a group of one of the following formulae:
when A is A2, H or a group of one of the following formulae:
provided that at least one of Ra and Rb is not H;
RY and RZ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the carbon atom to which they are attached a C3-C10 cycloalkyl group;
X represents Cl or a group the following formula:
RX represents a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, a phenyl group, a C5-C10-membered heteroaryl;
said C1-C10 linear or branched alkyl group, and C3-C10 cycloalkyl group being optionally substituted by at least one group selected from:
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
a —ORi group;
an amine of formula —NRi′Ri″;
said phenyl and C5-C10-membered heteroaryl being optionally substituted by at least one group selected from:
a C1-C10 linear or branched alkyl group;
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
an halogen;
a —ORi group;
an amine of formula —NRi′Ri″;
a nitrile;
a nitro group;
Ri and Rii each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group;
Ri′ and Ri″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group;
Rii′ and Rii″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group.

### Claim 3 (depends on 1)

The method according to claim 1, wherein formula (I) is formula (IA):
and
Ra and Rb are as defined in claim 1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein formula (I) is formula (IC):
and
Ra is as defined in claim 1.

### Claim 5 (depends on 4)

The method according to claim 4 wherein Ra represents a group of the following formula:
X representing in particular a group of the following formula:

### Claim 6 (depends on 1)

The method according to claim 1, wherein RX represents a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an aryl, a C5-C10-membered heteroaryl;
said C1-C10 linear or branched alkyl group, C3-C10 cycloalkyl group and C5-C10-membered heteroaryl being optionally substituted as defined in claim 1;
said aryl or C5-C10-membered heteroaryl being optionally substituted by at least one group selected from:
a C1-C10 linear or branched alkyl group;
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
—F;
a —ORi group; two adjacent —ORi groups forming possibly with the two C atoms bearing said —ORi groups a 1,4-dioxane ring;
an amine of formula —NRi′Ri″;
a nitrile;
a nitro group;
a CF3 group.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the compound is any one of the following formulae:

### Claim 8 (depends on 1)

The method according to claim 1, wherein said cancer is selected from the group comprising prostate cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, pituitary adenomas and Cushing's disease.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the compound is administered in an amount effect to inhibit USP2 and/or USP8.

### Claim 10 (depends on 9)

The method according to claim 9 wherein the compound is administered in an amount effective to inhibit USP2, and said cancer being selected from the group comprising prostate cancer, bladder cancer and breast cancer.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the compound is any one of the following formulae:

### Claim 12 (depends on 9)

The method according to claim 9, wherein the compound is administered in an amount effect to inhibit USP8, and said cancer being selected from the group comprising lung cancer, pituitary adenomas and Cushing's disease.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the compound is any one of the following formulae:

### Claim 14

A pharmaceutical composition comprising
a compound of following formula (I), or
a stereoisomeric form, a mixture of stereoisomeric forms or a pharmaceutically acceptable salt form thereof,
in admixture with at least one pharmaceutically acceptable excipient.
wherein:
A is selected from the group comprising:
Ra and Rb each independently represent:
when A is A1 or A3, a group of one of the following formulae:
when A is A2, H or a group of one of the following formulae:
provided that at least one of Ra and Rb is not H;
RY and RZ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the carbon atom to which they are attached a C3-C10 cycloalkyl group;
X represents Cl or a group of the following formula:
RX represents a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, a aryl, a C5-C10-membered heteroaryl;
said C1-C10 linear or branched alkyl group, and C3-C10 cycloalkyl group being optionally substituted by at least one group selected from:
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
a —ORi group;
an amine of formula —NRi′Ri″;
said aryl and C5-C10-membered heteroaryl being optionally substituted by at least one group selected from:
a C1-C10 linear or branched alkyl group;
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
an halogen;
a —ORi group; two adjacent —ORi groups forming possibly with the two C atoms bearing said —ORi groups a 1,4-dioxane ring;
an amine of formula —NRi′Ri″;
a nitrile;
a nitro group;
a CF3 group;
Ri and Rii each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group;
Ri′ and Ri″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group;
Rii′ and Rii″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group.

### Claim 15

A compound of following formula (II):
wherein:
A is selected from the group comprising:
Ra and Rb each independently represent:
when A is A1 or A3, a group of one of the following formulae:
when A is A2, H or a group of one of the following formulae:
provided that at least one of Ra and Rb is not H;
RY and RZ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the carbon atom to which they are attached a C3-C10 cycloalkyl group;
X represents Cl or a group of the following formula:
RX represents a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, a aryl, a C5-C10-membered heteroaryl;
said C1-C10 linear or branched alkyl group, and C3-C10 cycloalkyl group being optionally substituted by at least one group selected from:
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
a —ORi group;
an amine of formula —NRi′Ri″;
said aryl and C5-C10-membered heteroaryl being optionally substituted by at least one group selected from:
a C1-C10 linear or branched alkyl group;
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
an halogen;
a —ORi group; two adjacent —ORi groups forming possibly with the two C atoms bearing said —ORi groups a 1,4-dioxane ring;
an amine of formula —NRi′Ri″;
a nitrile;
a nitro group;
a CF3 group;
Ri and Rii each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group;
Ri′ and Ri″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group;
Rii′ and Rii″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group;
and the stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salts forms thereof;
provided that said compound is not of one of the following formulae:

### Claim 16 (depends on 15)

A compound according to claim 15, wherein Ra and Rb each independently represent a group of the following formula:
X represents a group of the following formula:
RX represents a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, a aryl, a C5-C10-membered heteroaryl;
said C1-C10 linear or branched alkyl group, and C3-C10 cycloalkyl group being optionally substituted by at least one group selected from:
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
a —ORi group;
an amine of formula —NRi′Ri″;
said C5-C10-membered heteroaryl being optionally substituted by at least one group selected from:
a C1-C10 linear or branched alkyl group;
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
an halogen;
a —ORi group; two adjacent —ORi groups forming possibly with the two C atoms bearing said —ORi groups a 1,4-dioxane ring;
an amine of formula —NRi′Ri″;
a nitrile;
a nitro group;
a CF3 group;
said aryl being substituted by at least one group selected from:
a C1-C10 linear or branched alkyl group;
a C3-C10 cycloalkyl group;
a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
an halogen;
a —ORi group; two adjacent —ORi groups forming possibly with the two C atoms bearing said —ORi groups a 1,4-dioxane ring;
an amine of formula —NRi′Ri″;
a nitrile;
a nitro group;
a CF3 group;
provided that, when the RX group=phenyl is substituted by a C1-C10 linear or branched alkyl group, said phenyl is substituted by a further group as defined above.
